La catena delle opzioni mostra i dati chiave delle opzioni azionarie di PaxMedica a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per PaxMedica..

PaxMedica (OTC:PXMD) Azioni, Catena delle Opzioni

PaxMedica

PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.

PaxMedica Inc

Apple Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) massive $60+ billion cash pile is once again <a href="https://www.benzinga.com/quote/AAPL/news">in the spotlight</a> &#8211; and with rivals <a href="https://www.benzinga.com/topic/artificial-intelligence">racing ahead in AI</a>, investors are wondering: is it finally time for Apple to make a bold move?
The discussion heated up this week after Apple confirmed that <a href="https://www.benzinga.com/markets/tech/25/07/46311533/jeff-williams-once-tipped-as-tim-cooks-successor-to-retire-from-apple">COO Jeff Williams will retire in 2025</a>, marking a rare leadership shake-up at the famously stable company. While some see it as a routine transition, others say it&#8217;s the opening Apple needs to shift its approach &#8211; particularly on artificial intelligence.
<h2 class="wp-block-heading">AI Spending Gap: Apple Can Afford to Catch Up Fast</h2>
While Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and Alphabet Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Google have made bold AI acquisitions or launched internal platforms (OpenAI partnerships, Gemini, LLaMA, etc.), Apple has largely sat on the sidelines &#8211; despite having one of the biggest acquisition budgets in the game.
<ul class="wp-block-list">
<li>Read Also: <a href="https://www.benzinga.com/markets/tech/25/07/46301582/metas-ai-empire-grows-fueled-by-openai-deepmind-apple-defectors">Meta&#8217;s AI Empire Grows — Fueled By OpenAI, DeepMind, Apple Defectors</a></li>
</ul>
While analysts speculate about Apple's next move following the COO exit, the raw numbers suggest it could reshape the AI landscape practically overnight—if it chose to.
Wedbush analyst Dan Ives has pointed out potential AI targets like Perplexity, but others believe Apple should think even bigger. Two names at the top of that list? Datadog Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>), valued at around $48 billion; and Tempus AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), valued at approximately $10.4 billion.
Apple's cash reserve &#8211; about $60 billion &#8211; is more than just a cushion for rainy days. It's a strategic asset that dwarfs the entire market capitalizations of some of the rising tech players. Stripping away real-world constraints like deal feasibility, regulatory approval, or strategic fit, Apple's $60 billion cash reserve is large enough—at least on paper—to outright acquire both Datadog and Tempus AI.
In short: if Apple wanted to, and if no constraining rules applied, it has enough cash to scoop up both companies and still have money left over.
<h2 class="wp-block-heading">Leadership Change Could Signal Strategy Shift</h2>
The decentralization of Jeff Williams' role across hardware and operations leaders could loosen Apple's famously tight structure &#8211; and perhaps invite more aggressive bets. The market responded mildly, with shares up 0.5%, but the potential is anything but mild.
If Apple really wants to make noise in AI, it's got the ammo. Now investors are waiting to see if it pulls the trigger.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46342321/nvidia-microsoft-apple-smash-10-trillion-is-this-peak-tech">Nvidia, Microsoft, Apple Smash $10 Trillion—Is This Peak Tech?</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Tech

Trading Ideas

AAPL

DDOG

GOOG

GOOGL

MSFT

Apple Acquisition Buzz: Its $60 Billion War Chest Is Enough To Buy Datadog And Tempus

Morgan Stanley analyst Terence Flynn maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Equal-Weight and raises the price target from $169 to $171.

News

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Johnson & Johnson, Raises Price Target to $171

Barclays analyst Benjamin Budish maintains Blue Owl Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) with a Overweight and raises the price target from $21 to $23.

Barclays Maintains Overweight on Blue Owl Capital, Raises Price Target to $23

Morgan Stanley analyst Terence Flynn maintains Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Underweight and lowers the price target from $36 to $34.

Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Lowers Price Target to $34

Barclays analyst Benjamin Budish maintains Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) with a Equal-Weight and raises the price target from $136 to $168.

Barclays Maintains Equal-Weight on Blackstone, Raises Price Target to $168

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight and lowers the price target from $755 to $754.

REGN

Morgan Stanley Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $754

Barclays analyst Benjamin Budish maintains BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) with a Overweight and raises the price target from $990 to $1220.

Barclays Maintains Overweight on BlackRock, Raises Price Target to $1220

Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) with a Overweight and raises the price target from $80 to $81.

LEGN

Morgan Stanley Maintains Overweight on Legend Biotech, Raises Price Target to $81

Barclays analyst Nicholas Campanella maintains Atmos Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATO#NYSE">ATO</a>) with a Equal-Weight and lowers the price target from $156 to $153.

Barclays Maintains Equal-Weight on Atmos Energy, Lowers Price Target to $153

XRP's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) has broken above $2.39 for the first time since May 23, buoyed by growing whale accumulation and bullish momentum around Ripple's ecosystem. 
Market watchers now see signs of <a href="https://www.benzinga.com/money/ripple-xrp-price-prediction">an imminent breakout.</a>
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Price</td>
<td>Market Cap</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>XRP</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.44</td>
<td>&nbsp;$144.4 billion</td>
<td>+7.8%</td>
</tr>
<tr>
<td>Bitcoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$111,368.12</td>
<td>&nbsp;$2.2 trillion</td>
<td>+1.6%&nbsp;</td>
</tr>
<tr>
<td>Ethereum</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,771.92</td>
<td>&nbsp;$335.1 billion</td>
<td>+7.4%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Cryptoinsightuk <a href="https://x.com/Cryptoinsightuk/status/1943233384819425509">noted</a> that XRP has cleared a key resistance level and is now holding it as hourly support. 
While yesterday's close hinted at bullish continuation, he says a strong close today would confirm a full-blown rally. Similar breakouts in the past have led to explosive moves, signaling what he calls potential "fireworks ahead."
Oscar Ramos, <a href="https://x.com/thecryptobasic/status/1943298136878772542">quoted </a>by Crypto Basic, is urging investors to go &#8220;all-in&#8221; on XRP, calling it a &#8220;must-have&#8221; in bullish portfolios. With Bitcoin hitting new highs at $112,000, altcoins like XRP are following with renewed strength. Ripple's progress with its RLUSD stablecoin and utility expansion is helping drive the sentiment shift.
Statistics: Santiment <a href="https://x.com/santimentfeed/status/1943017401009713342">data</a> shows XRP has reached a 7-week high, surpassing $2.39 for the first time since May 23. 
Whale activity is increasing, with 2,742 wallets now holding at least 1 million XRP, just one short of the all-time high. These large holders now control 47.32 billion XRP, signaling strong confidence in the asset's future.
Coinglass data shows XRP open interest increased 3.9% in a single day while derivatives trading volume expanded by 20.3%. 
Short liquidations of $7.97 million in the past 24 hours, continue to rise for the second consecutive day, implying traders forced to close their positions in the wake of XRP's rally.
Community News: Ripple <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46323539/xrp-boosted-4-by-ripples-stablecoin-partnership-with-bny-mellon">announced</a> that BNY, America's oldest running bank, will act as primary custodian for reserves backing its RLUSD stablecoin. The move aims to accelerate institutional trust and adoption.
Ripple is also actively pursuing a national bank charter and Federal Reserve master account to further legitimize RLUSD, which now <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46318111/xrp-eyes-2-40-as-ripples-rlusd-stablecoin-smashes-500m-market-cap">boasts </a>a more than $500 million market cap, making it the eighth-largest stablecoin after surpassing TrueUSD.
CEO Brad Garlinghouse reiterated that XRP's regulatory clarity is now well established, calling this a green light for broader adoption and use.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46327959/xrp-spikes-3-is-a-breakout-imminent">XRP Spikes 3%: Is A Breakout Imminent?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$XRP

XRP Breaks Above $2.40 For First Time Since May: How High Can It Go?

Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) with a Overweight and raises the price target from $132 to $133.

BNTX

Morgan Stanley Maintains Overweight on BioNTech, Raises Price Target to $133

Morgan Stanley analyst Terence Flynn maintains Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Overweight and raises the price target from $1133 to $1135.

Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1135

Barclays analyst Benjamin Budish maintains Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) with a Overweight and raises the price target from $182 to $200.

ARES

Barclays Maintains Overweight on Ares Management, Raises Price Target to $200

Morgan Stanley analyst Terence Flynn maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Equal-Weight and lowers the price target from $348 to $328.

UTHR

Morgan Stanley Maintains Equal-Weight on United Therapeutics, Lowers Price Target to $328

Morgan Stanley analyst Betsy Graseck maintains Ally Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) with a Overweight and raises the price target from $39 to $47.

ALLY

Morgan Stanley Maintains Overweight on Ally Financial, Raises Price Target to $47

Barclays analyst Benjamin Budish maintains Apollo Asset Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) with a Overweight and raises the price target from $156 to $168.

Barclays Maintains Overweight on Apollo Asset Management, Raises Price Target to $168

Morgan Stanley analyst Betsy Graseck maintains American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) with a Equal-Weight and raises the price target from $250 to $311.

Morgan Stanley Maintains Equal-Weight on American Express, Raises Price Target to $311

Barclays analyst Eric Beaumont maintains American Water Works Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWK#NYSE">AWK</a>) with a Underweight and lowers the price target from $138 to $128.

Barclays Maintains Underweight on American Water Works Co, Lowers Price Target to $128

Barclays analyst Brandon Oglenski maintains American Airlines Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) with a Equal-Weight and raises the price target from $11 to $12.

Barclays Maintains Equal-Weight on American Airlines Group, Raises Price Target to $12

<a href="https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_07102025_SNGX_Bautz.pdf" title="https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_07102025_SNGX_Bautz.pdf">https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_07102025_SNGX_Bautz.pdf</a>

Comments

PaxMedica

PaxMedica (PXMD) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO